Implementation and physician behavior change : an industry perspective.
Clinical practice guidelines are omnipresent and increasing in number; however, their utility and applicability are questioned. A great deal of effort is expended in their creation, but how they reach their ultimate customers is very variable. The pharmaceutical industry has considerable resources that may assist in this process; however, they need to be more involved in the development of clinical practice guidelines. This can happen only if both guideline developers and industry set aside their fears, concerns, and prejudices and collectively try to improve health care through more appropriate management of patients.
Tillotson
G S
GS
International Scientific Relations, Bayer Corporation, West Haven, CT 06516, USA. glenn.tillotson.b@bayer.com
D017714:Community-Acquired Infections / Q000188:drug therapy; D003625:Data Collection; D004345:Drug Industry / Q000191:economics*; D006801:Humans; D018410:Pneumonia, Bacterial / Q000188:drug therapy; D017410:Practice Guidelines as Topic